PD-L1 expression in meningiomas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies. Recent identification of PD-L1 expression in some types of cancer cells has raised the possibility that its inhibition of host immunosurveillance may be part of the mechanism. Thus, tumor cell PD-L1 might be a useful new target for chemotherapy in PD-L1- bearing tumors. Several a monoclonal antibodies against PD-L1 are now in use in the management of treatment refractory or metastatic non-small cell carcinoma of the lung, metastatic renal cell carcinoma, melanoma and other malignancies. The extent of PD-L1 expression is not established in meningiomas. Depending on the degree of expression, anti-PD-L1, might be an effective treatment for meningiomas. In this study, we used a monoclonal antibody, approved by the FDA for clinical screening to evaluate PD-L1 expression in a series of 58 meningiomas including 13 with bone, brain or dural invasion. PD-L1 immunoreactivity was detected in 1 of 31 grade I, 1 of 16 grade II and 2 of 11 WHO grade III meningiomas. PD-L1 was seen in 1 grade II tumor invading brain and 1 grade III tumor invading bone but was not at sites of invasion. In each case, immunoreactivity was scored as limited. The findings suggest anti-PD-L1 therapy might be worth evaluating in a select number of positive tumors but its overall applicability may be limited.

Original languageEnglish (US)
Pages (from-to)149-151
Number of pages3
JournalJournal of Clinical Neuroscience
Volume57
DOIs
StatePublished - Nov 1 2018
Externally publishedYes

Fingerprint

Meningioma
Neoplasms
Monoclonal Antibodies
Immunologic Monitoring
Bone and Bones
Drug Therapy
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Brain Neoplasms
Immunosuppression
Melanoma
Therapeutics
Brain

All Science Journal Classification (ASJC) codes

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

PD-L1 expression in meningiomas. / Johnson, Mahlon.

In: Journal of Clinical Neuroscience, Vol. 57, 01.11.2018, p. 149-151.

Research output: Contribution to journalArticle

@article{3485a2447b2b4c86802e89426a24e430,
title = "PD-L1 expression in meningiomas",
abstract = "The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies. Recent identification of PD-L1 expression in some types of cancer cells has raised the possibility that its inhibition of host immunosurveillance may be part of the mechanism. Thus, tumor cell PD-L1 might be a useful new target for chemotherapy in PD-L1- bearing tumors. Several a monoclonal antibodies against PD-L1 are now in use in the management of treatment refractory or metastatic non-small cell carcinoma of the lung, metastatic renal cell carcinoma, melanoma and other malignancies. The extent of PD-L1 expression is not established in meningiomas. Depending on the degree of expression, anti-PD-L1, might be an effective treatment for meningiomas. In this study, we used a monoclonal antibody, approved by the FDA for clinical screening to evaluate PD-L1 expression in a series of 58 meningiomas including 13 with bone, brain or dural invasion. PD-L1 immunoreactivity was detected in 1 of 31 grade I, 1 of 16 grade II and 2 of 11 WHO grade III meningiomas. PD-L1 was seen in 1 grade II tumor invading brain and 1 grade III tumor invading bone but was not at sites of invasion. In each case, immunoreactivity was scored as limited. The findings suggest anti-PD-L1 therapy might be worth evaluating in a select number of positive tumors but its overall applicability may be limited.",
author = "Mahlon Johnson",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.jocn.2018.08.023",
language = "English (US)",
volume = "57",
pages = "149--151",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - PD-L1 expression in meningiomas

AU - Johnson, Mahlon

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies. Recent identification of PD-L1 expression in some types of cancer cells has raised the possibility that its inhibition of host immunosurveillance may be part of the mechanism. Thus, tumor cell PD-L1 might be a useful new target for chemotherapy in PD-L1- bearing tumors. Several a monoclonal antibodies against PD-L1 are now in use in the management of treatment refractory or metastatic non-small cell carcinoma of the lung, metastatic renal cell carcinoma, melanoma and other malignancies. The extent of PD-L1 expression is not established in meningiomas. Depending on the degree of expression, anti-PD-L1, might be an effective treatment for meningiomas. In this study, we used a monoclonal antibody, approved by the FDA for clinical screening to evaluate PD-L1 expression in a series of 58 meningiomas including 13 with bone, brain or dural invasion. PD-L1 immunoreactivity was detected in 1 of 31 grade I, 1 of 16 grade II and 2 of 11 WHO grade III meningiomas. PD-L1 was seen in 1 grade II tumor invading brain and 1 grade III tumor invading bone but was not at sites of invasion. In each case, immunoreactivity was scored as limited. The findings suggest anti-PD-L1 therapy might be worth evaluating in a select number of positive tumors but its overall applicability may be limited.

AB - The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies. Recent identification of PD-L1 expression in some types of cancer cells has raised the possibility that its inhibition of host immunosurveillance may be part of the mechanism. Thus, tumor cell PD-L1 might be a useful new target for chemotherapy in PD-L1- bearing tumors. Several a monoclonal antibodies against PD-L1 are now in use in the management of treatment refractory or metastatic non-small cell carcinoma of the lung, metastatic renal cell carcinoma, melanoma and other malignancies. The extent of PD-L1 expression is not established in meningiomas. Depending on the degree of expression, anti-PD-L1, might be an effective treatment for meningiomas. In this study, we used a monoclonal antibody, approved by the FDA for clinical screening to evaluate PD-L1 expression in a series of 58 meningiomas including 13 with bone, brain or dural invasion. PD-L1 immunoreactivity was detected in 1 of 31 grade I, 1 of 16 grade II and 2 of 11 WHO grade III meningiomas. PD-L1 was seen in 1 grade II tumor invading brain and 1 grade III tumor invading bone but was not at sites of invasion. In each case, immunoreactivity was scored as limited. The findings suggest anti-PD-L1 therapy might be worth evaluating in a select number of positive tumors but its overall applicability may be limited.

UR - http://www.scopus.com/inward/record.url?scp=85054306140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054306140&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2018.08.023

DO - 10.1016/j.jocn.2018.08.023

M3 - Article

C2 - 30153998

AN - SCOPUS:85054306140

VL - 57

SP - 149

EP - 151

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

ER -